⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4437553 | 0.74 | — | — | |
| SCHEMBL31435813 | 0.64 | — | — | |
| SCHEMBL20357471 | 0.62 | — | — | |
| SCHEMBL5610703 | 0.61 | — | — | |
| SCHEMBL3716647 | 0.61 | — | — | |
| SCHEMBL29238557 | 0.58 | — | — | |
| SCHEMBL23894391 | 0.58 | — | — | |
| SCHEMBL14910991 | 0.57 | — | — | |
| SCHEMBL11725550 | 0.56 | — | — | |
| SCHEMBL20923479 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109415630-A | Liquid-crystal composition, mixture, element and tunable light device | 日东电工株式会社 | 2019-03-01 | — | — | CN | disclosed |
| US-9227914-B2 | Calcilytic compounds | GlaxoSmithKline, LLC (US) | 2016-01-05 | — | — | US | disclosed |
| CN-104789232-A | Pyran ring-containing negative liquid crystal compound and preparation method thereof | UNIV SHAANXI NORMAL | 2015-07-22 | — | — | CN | disclosed |
| US-20150183723-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2015-07-02 | — | — | US | disclosed |
| US-8980950-B2 | Calcilytic compounds | GlaxoSmithKline, LLC (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140057980-A1 | CALCILYTIC COMPOUNDS | GlaxoSmithKline, LLC (US) | 2014-02-27 | — | — | US | disclosed |
| US-8586631-B2 | Calcilytic compounds | GlaxoSmithKline, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130158114-A1 | Calcilytic Compounds | GlaxoSmithKline, LLC (US) | 2013-06-20 | — | — | US | disclosed |
| US-8399517-B2 | Calcilytic compounds | GlaxoSmithKline, LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110054021-A1 | Calcilytic Compounds | GLAXOSMITHKLINE LLC | 2011-03-03 | — | — | US | disclosed |
| US-7829594-B2 | calcium receptor antagonists such as 3-{3,4-Difluoro-5-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxyl]-phenyl}-propionic acid, used to increase serum parathyroid hormone levels in mammals | GlaxoSmithKline, LLC (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090163589-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM. CORP. | 2009-06-25 | — | — | US | disclosed |
| US-7514473-B2 | Calcilytic compounds | SMITHKLINE BEECHAM, CORP. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20060058391-A1 | Calcilytic compounds | SMITHKLINE BEECHAM CORPORATION | 2006-03-16 | — | — | US | disclosed |
| EP-1569892-A2 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004047751-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |